{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:29:25Z","timestamp":1792654165190,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5364,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:p>AmBisome (NeXstar Pharmaceuticals, San Dimas, CA) is a unilamellar liposomal formulation of amphotericin B that was recently approved for use as empirical treatment for presumed fungal infections in febrile neutropenic patients and for aspergillosis, candidiasis, and cryptococcosis infections refractory to amphotericin B. It is a small closed microscopic sphere (&lt;100 nm in diameter) with an inner aqueous core (i.e., a true liposome). AmBisome remains as an intact sphere <jats:italic>in vitro<\/jats:italic> and for prolonged periods of time <jats:italic>in vivo<\/jats:italic> during the processes of systemic transport and pharmacologic action. As a consequence of its size and <jats:italic>in vivo<\/jats:italic> stability, AmBisome has physiochemical properties and a pharmacokinetic profile that are considerably different from those of currently available lipid\u2010complexed amphotericin B formulations, with greatly increased area under the plasma concentration\u2014time curve and much lower clearance at equivalent doses. AmBisome liposomes can be seen to accumulate at sites of fungal infection. Disruption of AmBisome liposomes occurs after attachment to the fungal cell wall and results in amphotericin B binding to fungal cell membrane ergosterol with subsequent cell lysis. AmBisome has been shown to penetrate the cell wall of both extracellular and intracellular forms of susceptible fungi.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1998.tb04464.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:17:45Z","timestamp":1362766665000},"page":"583-592","source":"Crossref","is-referenced-by-count":178,"title":["AmBisome (Liposomal Amphotericin B): A Comparative Review"],"prefix":"10.1002","volume":"38","author":[{"given":"G. W.","family":"Boswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Buell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bekersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"491","article-title":"Liposomal amphotericin B (AmBisome): realization of the drug delivery concept","volume":"62","author":"Fujii G","year":"1996","journal-title":"Surfactant Sci Ser"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_2.S133"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150729"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(92)90414-H"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.299"},{"key":"e_1_2_1_7_2","article-title":"Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","author":"Walsh TJ","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_8_2","first-page":"2764","volume-title":"Physicians Desk Reference","author":"Sequus Pharmaceuticals, Inc","year":"1998"},{"key":"e_1_2_1_9_2","first-page":"1516","volume-title":"Physicians Desk Reference","author":"The Liposome Company, Inc","year":"1988"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6122"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150731"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/123.4.341"},{"issue":"5","key":"e_1_2_1_13_2","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler\u2010Moore J","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_14_2","volume-title":"AmBisome Product Monograph: Mechanism of Action.","author":"NeXstar Pharmaceuticals, Inc.","year":"1996"},{"key":"e_1_2_1_15_2","volume-title":"Physicians Desk Reference.","year":"1996"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1996.32.5.379049"},{"key":"e_1_2_1_17_2","first-page":"12","article-title":"Non\u2010clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion","volume":"32","author":"Dayan AD","year":"1993","journal-title":"Round Table Series"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.315"},{"key":"e_1_2_1_19_2","first-page":"30","volume-title":"Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial","author":"Anaissie EJ","year":"1995"},{"issue":"1","key":"e_1_2_1_20_2","first-page":"544a","article-title":"Comparative analysis of liposomal and lipid complex amphotericin B preparations (ASH abstract 2426)","volume":"90","author":"Clark A","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/AAC.42.2.263","article-title":"Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B (AmBisome) in rats","volume":"42","author":"Boswell G","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1208"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.5.723"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.713"},{"key":"e_1_2_1_25_2","volume-title":"Prophylactic Treatment of Murine Candidiasis with Single High Dose AmBisome.","author":"Garcia A","year":"1996"},{"key":"e_1_2_1_26_2","volume-title":"The toxicokinetics of amphotericin B in dogs during a 30\u2010day intravenous toxicity study of AmBiosome (liposomal amphoteracin B)","author":"Bekersky I","year":"1996"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.299"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.886"},{"key":"e_1_2_1_29_2","volume-title":"Interaction of Fungizone and AmBisome with Whole Blood and Isolated Human Red Blood Cells. Report 232\u201093099.","author":"Adler\u2010Moore J"},{"key":"e_1_2_1_30_2","unstructured":"BuellD RiveraM GordonJ KlineS ThumaN:AmBisome rescue in patients who have received other lipid formulations of amphotericin B (abstract 026). In Proceedings of the Eighth Focus on Fungal Infections March 4\u20136 1998 Orlando FL."},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1991.tb03189.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1998.tb04464.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1998.tb04464.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T11:52:49Z","timestamp":1698493969000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1998.tb04464.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1002\/j.1552-4604.1998.tb04464.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04464.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}